Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1Hypertension 1Hot Flashes 1Diabetes Mellitus 1Depressive Disorder, Major 1Depression 1Cardiovascular Diseases 1Breast Neoplasms 1

Interventions

Cholecalciferol 4Nutrition Assessment 3Exercise 3Blood Pressure 3Atorvastatin 3acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Vitamin E 2Vitamin D 2Rosuvastatin Calcium 2Methods 2Metformin 2Gonadotropin-Releasing Hormone 2Geritol 2Fish Oils 2Fatty Acids, Omega-3 2Ethanol 2Educational Status 2Diet, Mediterranean 2Aspirin 2xinmailong 1sofosbuvir-velpatasvir drug combination 1pembrolizumab 1palbociclib 1ficlatuzumab 1beta Carotene 1amlodipine, atorvastatin drug combination 1Vorinostat 1Vitamin B 6 1Vitamin B 12 1Tumor Necrosis Factor Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cardiovascular Diseases × Desvenlafaxine Succinate × Clear all
NCT01803711 2017-12-27

Omega 3 FA Supplements as Augmentation in the Treatment of Depression

UConn Health

Phase 2/3 Terminated
6 enrolled 4 charts

Cardiovascular Diseases, Depression, Depressive Disorder, Major, Diabetes Mellitus, Hypertension, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡